(Q27852289)

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Acute promyelocytic leukemia. Therapy results and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

How I treat acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Mapping of human chromosomal regions related to neoplasia: Evidence from chromosomes 1 and 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Identification of a receptor for the morphogen retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The methyl-CpG binding protein MBD1 is required for PML-RARalpha function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Role of the polycomb repressive complex 2 in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Acute promyelocytic leukaemia: novel insights into the mechanisms of cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

A sumoylation site in PML/RARA is essential for leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Retinoic acid resistance in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Detection of the STAT5B-RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

JAK2 the future: therapeutic strategies for JAK-dependent malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

How to manage acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

The origin and evolution of mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1354-4

All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases

21 January 2018

1 reference

12 December 2020

The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion

1 reference

12 December 2020

Acute promyelocytic leukemia

1 reference

12 December 2020

Developmental analysis of murine Promyelocyte Leukemia Zinc Finger (PLZF) gene expression: implications for the neuromeric model of the forebrain organization.

1 reference

12 December 2020

Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia

1 reference

12 December 2020

Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells

1 reference

12 December 2020

A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features

1 reference

12 December 2020

A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation

1 reference

12 December 2020

Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia

1 reference

12 December 2020

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

1 reference

12 December 2020

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins

1 reference

12 December 2020

All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.

1 reference

12 December 2020

All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene

1 reference

12 December 2020

Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA)

1 reference

12 December 2020

The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia

1 reference

12 December 2020

Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway

1 reference

12 December 2020

Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation

1 reference

12 December 2020

Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy

1 reference

12 December 2020

Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.

1 reference

12 December 2020

Mutants strike again in APL

1 reference

12 December 2020

Novel agents in acute myeloid leukemia

1 reference

12 December 2020

All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan

1 reference

12 December 2020

Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements

1 reference

12 December 2020

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients

1 reference

12 December 2020

Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia

1 reference

12 December 2020

Results of APL 91 European trial combining ATRA and chemotherapy: presentation of APL 1993 trial

1 reference

12 December 2020